Olanzapine/Samidorphan Malate
Brand name: Lybalvi
Rank #353 of 500 drugs by total cost
$28.3M
Total Cost
18,294
Total Claims
$28.3M
Total Cost
720
Prescribers
$1,549
Cost per Claim
520
Beneficiaries
18,619
30-Day Fills
$39K
Avg Cost/Provider
25
Avg Claims/Provider
About Olanzapine/Samidorphan Malate
Olanzapine/Samidorphan Malate (sold as Lybalvi) was prescribed 18,294 times by 720 Medicare Part D providers in 2023, costing the program $28.3M. At $1,549 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 350 | Meloxicam (Meloxicam) | $28.6M | 4,714,084 |
| 351 | Triamcinolone Acetonide (Triamcinolone Acetonide) | $28.5M | 2,307,130 |
| 352 | Pitolisant Hcl (Wakix) | $28.4M | 2,361 |
| 353 | Olanzapine/Samidorphan Malate (Lybalvi) | $28.3M | 18,294 |
| 354 | Interferon Beta-1b (Betaseron) | $28.3M | 2,983 |
| 355 | Iloperidone (Fanapt) | $28.2M | 13,925 |
| 356 | Aflibercept (Eylea) | $28.0M | 10,899 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology